SCHEMBL4289249

SCHEMBL4289249

COc1ccc(-n2c(C=CN(C)C)c([N+](=O)[O-])c3ccc(O)c(CN4CCCCC4)c32)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.71
ALDH1A1 P00352 7/20 0.71
HTT P42858 3/20 0.71
NPSR1 Q6W5P4 2/20 0.71
LMNA P02545 2/20 0.54
PKM P14618 1/20 0.51
KDM4E B2RXH2 7/20 0.44
GAA P10253 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CLK1 P49759 1/20 0.38
GSK3B P49841 1/20 0.38
DYRK1A Q13627 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37
TSHR P16473 1/20 0.37
GLA P06280 1/20 0.36
HPGD P15428 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289246 1.00 MAPT (0.71) MAPTALDH1A1HTTNPSR1LMNA
SCHEMBL4288368 0.92 ALDH1A1 (0.60) MAPTALDH1A1HTTNPSR1LMNA
SCHEMBL4288372 0.92 ALDH1A1 (0.60) MAPTALDH1A1HTTNPSR1LMNA
SCHEMBL4288413 0.86 ALDH1A1 (0.73) MAPTALDH1A1HTTNPSR1LMNA
SCHEMBL4288409 0.86 ALDH1A1 (0.73) MAPTALDH1A1HTTNPSR1LMNA
SCHEMBL4062560 0.84 MAPT (0.98) MAPTALDH1A1HTTNPSR1LMNA
Hydrochloric Acid SCHEMBL4290512 0.83 MAPT (1.00) MAPTALDH1A1HTTNPSR1LMNA
SCHEMBL4246818 0.83 ALDH1A1 (0.56) MAPTALDH1A1HTTNPSR1LMNA
SCHEMBL4241354 0.78 ALDH1A1 (0.49) MAPTALDH1A1HTTNPSR1LMNA
SCHEMBL4289356 0.76 MAPT (0.73) MAPTALDH1A1HTTNPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883504-B2 Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line ASAHI KASEI KABUSHIKI KAISHA (JP) 2014-11-11 US disclosed
US-20090155906-A1 CELL DIFFERENTIATION SUPPRESSING AGENT, METHOD OF CULTURING CELLS USING THE SAME, CULTURE SOLUTION, AND CULTURED CELL LINE MIYABAYASHI TOMOYUKI 2009-06-18 US disclosed
EP-1640449-A1 CELL DIFFERENTIATION INHIBITING AGENT, CELL CULTURE METHOD USING THE SAME, CULTURE MEDIUM AND CULTURED CELL LINE Asahi Kasei Kabushiki Kaisha (JP) 2006-03-29 EP disclosed
US-20050153941-A1 Increasing Stage Specific Embryonic Antigen (SSEA) and Nanog gene levels; culturing a stem cell using a low molecular weight derivative of 2-(phenylazo)-2-(3,4-dihydro-2H-isoquinoline-1-ylidene) or N-phenylindole ASAHI KASEI KABUSHIKI KAISHA (JP) 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153941-A1 Increasing Stage Specific Embryonic Antigen (SSEA) and Nanog gene levels; culturing a stem cell using a low molecular weight derivative of 2-(phenylazo)-2-(3,4-dihydro-2H-isoquinoline-1-ylidene) or N-phenylindole MKI67, ALPG, NES MAPT 4659/4885ALDH1A1 38/4885HTT 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.